Objectives: This study aims to determine whether patients receiving antiretroviral prescription medications to treat HIV/AIDS through a 340B program exhibited differences in medication adherence rates as compared to comparable patients whose medications were not received through a 340B program. MethOds: Using data from Walgreens, 2008 -2014, we conducted a retrospective propensity matched cohort study comparing medication adherence rates for a national sample of HIV/ AIDS patients who received medications through a 340B program to a matched cohort of HIV/AIDS patients whose antiretroviral medications were not received through a 340B program. Patients were matched by age, gender, initial dispensing year, length of HIV therapy, length of medication therapy, and 91 therapeutic classes. Adherence to antiretroviral medications was measured using the proportion of days covered (PDC) metric. One-to-one matching resulted in 9,437 matched pairs. We used mixed modelling methods to assess statistical differences. Results: Mean PDC was higher for the 340B cohort versus the comparison cohort (84% vs. 77%, p< .001). Forty-five percent of the 340B cohort had medication adherence rates (PDC) greater than or equal to the 95% adherence threshold for HIV/AIDS patients compared to the comparison cohort where 41% of patients were adherent according to this threshold (p< .001). cOnclusiOns: These results show that patients with HIV/AIDS who receive antiretroviral medications through a 340B program had higher medication adherence rates, which have been associated with better clinical outcomes. Various factors, such as lower patient costs or improved access to pharmacies, may impact patient adherence, and we will explore such factors on adherence in future research on the 340B Program.
IPAs were expected to be reviewed at the midpoint of the agreement. Conclusions: Challenges similar to other jurisdictions were observed in Malaysia, concerns on data availability, responsibility of the stakeholders and the need for a legal framework. Most stakeholders responded positively that the IPAs would grow. Considering the complexities of implementing outcome/ performance-based IPAs, the use of a hybrid IPAs should be assessed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.